Europe Infectious Disease Therapeutics Market was valued at USD 18 Billion in 2022 and is projected to reach USD 31 Billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030.
In recent years, the Europe Infectious Disease Therapeutics Market has experienced significant growth, driven by the rising prevalence of infectious diseases and substantial investments in research and development (R&D). According to Business Market Insights, the market was valued at approximately US$35.45 billion in 2022 and is projected to reach US$49.10 billion by 2030, registering a compound annual growth rate (CAGR) of 4.2% during this period.
One of the primary factors contributing to this growth is the increasing incidence of infectious diseases such as HIV, hepatitis, tuberculosis, and influenza. The HIV segment, for instance, held a 35.6% share of the market in 2022, amounting to US$12.62 billion, and is anticipated to reach US$18.23 billion by 2030, expanding at a CAGR of 4.7%.
The market is segmented based on drug class, with anti-viral, anti-bacterial, and anti-fungal therapies being the major categories. In 2022, the anti-viral segment held a 44.3% market share, totaling US$15.70 billion, and is projected to reach US$21.96 billion by 2030, growing at a CAGR of 4.3%. This growth underscores the critical need for effective antiviral treatments in combating prevalent infections.
Germany stands out as a key player in the European market, capturing a 26.5% share in 2022, valued at US$9.40 billion. The country's robust healthcare infrastructure and strong focus on R&D have positioned it as a leader in infectious disease therapeutics. Notably, companies like Atriva Therapeutics GmbH are developing innovative treatments, such as ATR-002, aimed at blocking the viral propagation of SARS-CoV-2.
Industry requirements are evolving to meet the challenges posed by emerging infectious diseases and antibiotic resistance. Pharmaceutical companies are increasingly investing in R&D to develop novel antimicrobial therapies. For example, GSK has set ambitious growth targets, aiming to generate over £40 billion in revenue by 2031, reflecting a £7 billion increase from four years ago. This strategy includes the development of new vaccines like Arexvy and Shingrix, as well as advancements in cancer treatment.
Additionally, the integration of advanced technologies, such as artificial intelligence (AI), is becoming essential in early disease detection and drug development. Sanofi, for instance, is focusing on critical drug developments, including new RSV treatments, and is leveraging AI for early disease detection. This approach highlights the industry's commitment to innovation in addressing infectious diseases.
Moreover, the emergence of interferon-free regimens and increased awareness programs are trends shaping the infectious diseases therapeutics industry. Advances in rapid diagnostics, enabling earlier and faster detection of infections, significantly influence medical outcomes. Technologies such as lateral flow and agglutination tests, combined with portable devices, offer viable solutions for timely diagnosis and treatment.
In conclusion, the Europe Infectious Disease Therapeutics Market is poised for substantial growth, driven by the rising prevalence of infectious diseases, increased R&D investments, and the integration of advanced technologies. The industry's focus on developing novel therapies and improving diagnostic capabilities is essential in addressing current and future challenges in infectious disease management.
Get an In-Depth Research Analysis of the Europe Infectious Disease Therapeutics Market Size And Forecast [2025-2032]
Novartis AG
Gilead
GlaxoSmithKline plc
Janssen Pharmaceutical Inc
F. Hoffmann-La Roche Ltd.
BioCryst Pharmaceuticals Inc
Merck & Co. Inc
Boehringer Ingelheim GmbH
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Infectious Disease Therapeutics Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Infectious Disease Therapeutics Market
Bacterial Infections
Viral Infections
Fungal Infections
Parasitic Infections
Antibiotics
Antivirals
Antifungals
Antiparasitics
Immunotherapies
Oral
Injectable
Topical
Inhalation
Pediatric
Adult
Geriatric
Immunocompromised Patients
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Infectious Disease Therapeutics Market Research Analysis
1. Introduction of the Europe Infectious Disease Therapeutics Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Infectious Disease Therapeutics Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Infectious Disease Therapeutics Market, By Type
6. Europe Infectious Disease Therapeutics Market, By Application
7. Europe Infectious Disease Therapeutics Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Infectious Disease Therapeutics Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/